Novartis AG (NVS)
NVS Stock Price Chart
Key Info
| Market Cap | 225.24B |
| Revenue (ttm) | 48.68B |
| Net Income (ttm) | 11.73B |
| Shares Out | 2.31B |
| EPS (ttm) | 3.09 |
| PE Ratio | 29.58 |
| Forward PE | n/a |
| Dividend | $3.09 |
| Dividend Yield | 3.38% |
Stock Quote
| Trading Day | December 4 |
| Last Price | $91.30 |
| Previous Close | $90.24 |
| Change ($) | 1.06 |
| Change (%) | 1.17% |
| Day's Open | 91.06 |
| Day's Range | 90.98 - 91.52 |
| Day's Volume | 449,122 |
| 52-Week Range | 70.67 - 99.01 |
NVS Stock News
EAST HANOVER, N.J., Dec. 1, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (...
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...
Novartis' shares are inexpensive and trade at a discount to its historic valuation range. Shares offer a solid dividend yield of 3.5% at current prices.
Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
On Tuesday, Swiss biopharma company Novartis AG (NYSE: NVS) announced a $2.5 billion share buyback program. The management also exhibited a heightened confidence level in its sales projections...
Basel, November 24, 20 20 — Novartis is hosting today its annual Meet Novartis Management event giving investors and industry analysts the opportunity to meet with key executives across the co...
As dividend growth investors, we know that wide moat stocks make a good starting point, but it is just one of many considerations on our hunt for high-quality dividend growth stocks. The stock...
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Basel, November 19 , 20 20 — Novartis announced today that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture r...
The digital press release with multimedia content can be accessed here:
Basel, November 19 , 20 20 — Novartis today announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean p...
Using traditional metrics, it seems in peril, but investors need to take a closer look in order to judge just how safe the payout is.
The digital press release with multimedia content can be accessed here:
Basel, November 6 , 20 20 — Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety o...
Basel, November 5, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial,...
Do you want to know how to invest in startups? Start by taking at look at these seven unicorn startups and their unique business models.
Novartis AG (NYSE:NVS) is expanding its gene therapy footprint by acquiring a venture capital-backed company focusing on treating vision loss that can lead to blindness.
The digital press release with multimedia content can be accessed here:
Basel, October 30, 2020 — Novartis today announced the receipt of marketing authorization from Japan's Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and I...
CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered...
Novartis AG (NYSE: NVS) announced Wednesday it has received the license for global rights to develop, manufacture, and commercialize two antiviral therapies of Molecular Partners AG (OTC: MLLC...
Basel, October 28 , 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular...
Novartis (NVS) CEO, Vas Narasimham on Q3 2020 Results - Earnings Call Transcript
Novartis AG's (NVS) CEO Vas Narasimhan on Q3 2020 Results - Quick Version Earnings Call Transcript
Shares of Novartis (SIX: NOVN) fell almost 4% Tuesday after the Swiss pharmaceuticals company reported lower-than-expected sales in the third quarter. Fundamental analysis: Higher income, low...
Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.
Shares of Novartis (NYSE:NVS) decreased 1.6% in pre-market trading after the company reported Q3 results.
Novartis CEO ‘Cautiously Optimistic' on Covid Impact in Fourth Quarter
Oct.27 -- Novartis Chief Executive Officer Vas Narasimhan discusses the business impact of Covid-19, the race for a vaccine, and the company's development of a coronavirus antibody treatment. ...
Novartis earnings beat third-quarter views while sales came in light. Full-year revenue guidance was in line for the Swiss drug giant.
Basel, October 27 , 2020 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said:
Here's a preview of pharma earnings coming out this week
Geoff Meacham, Bank of America Securities biopharmaceuticals research analyst, joins "Squawk Box" to discuss the high profile earnings reports expected out of the pharmaceutical industry.
Basel, October 26 , 20 20 — Novartis today announced positive Phase II interim analysis results for iptacopan (LNP023), an investigational oral treatment for C3 glomerulopathy (C3G), presented...
Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia.
Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best ...
In a conversation with ‘Fast Company’ Editor-in-Chief Stephanie Mehta, Novartis CEO Vas Narasimhan explained why the world failed to respond to the pandemic—and how we can eventually get back ...
EAST HANOVER, N.J., Oct. 3, 2020 /PRNewswire/ -- Novartis today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episod...
A House committee has issued detailed reports about some of their drug price increases.
Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.
Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvest...
Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with t...
Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.
Novartis: Finally In Position To Make Share Price Gains It Deserves
A Milan judge has seized 2.3 million euros ($2.7 million) from pharmaceutical multinational Novartis as part of a fraud investigation, a document seen by Reuters shows.
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1
EAST HANOVER, N.J., Sept. 16, 2020 /PRNewswire/ -- Today the Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and ...
Basel, September 16, 2020 — Novartis today announced the pricing of a EUR 1.85 billion sustainability-linked bond (SLB), reinforcing its commitment to ESG principles and the 2025 Patient Acces...
Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.
Novartis (NVS) announces positive data on Beovu from an ongoing late-stage study for the DME indication.
Basel, September 14, 2020 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP), has approved an update to the Beovu® (brolucizumab) Summary of Product Char...
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic are... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Nov 18, 1991 |
| Employees 110,000 | |
| Stock Exchange NYSE | Ticker Symbol NVS |
Financial Performance
In 2019, Novartis's revenue was $48.68 billion, an increase of 5.59% compared to the previous year's $46.10 billion. Earnings were $11.73 billion, a decrease of -6.97%.
Analyst Forecasts
The average 12-month stock price forecast for Novartis is 104.50, which is an increase of 14.46% from the latest price.